Metabolic activation and drug-induced liver injury: In vitro approaches for the safety risk assessment of new drugs

Journal of Applied Toxicology

Volumn 36, Issue 6, 2016, Pages 752-768

  Gómez Lechón, M José ^a,b   Tolosa, Laia ^a   Donato, M Teresa ^a,b,c  

^a INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Bioactivation; Covalent binding; DILI; Engineered cells; Hepatocytes; Hepatotoxicity; Idiosyncrasy; IPSCs; Microsomes; Reactive metabolites

Indexed keywords

CYTOCHROME P450; DRUG METABOLITE; NEW DRUG; RECOMBINANT PROTEIN;

ARTICLE; COVALENT BOND; DRUG SAFETY; ENZYME INACTIVATION; HUMAN; IN VITRO STUDY; LIVER CELL; LIVER TOXICITY; METABOLIC ACTIVATION; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; RISK ASSESSMENT; THREE DIMENSIONAL IMAGING; TOXIC HEPATITIS; ANIMAL; BIOLOGICAL MODEL; CELL CULTURE; CELL CULTURE TECHNIQUE; CELL LINE; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHEMISTRY; COCULTURE; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; LIVER; LIVER MICROSOME; METABOLISM; MICROFLUIDICS; PATHOLOGY; PRECLINICAL STUDY; PROCEDURES; RISK FACTOR; TISSUE SCAFFOLD; TRENDS;

ACTIVATION, METABOLIC; ANIMALS; CELL CULTURE TECHNIQUES; CELL LINE; CELLS, CULTURED; CHEMICAL AND DRUG INDUCED LIVER INJURY; COCULTURE TECHNIQUES; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; HUMANS; IN VITRO TECHNIQUES; LIVER; MICROFLUIDICS; MICROSOMES, LIVER; MODELS, BIOLOGICAL; PLURIPOTENT STEM CELLS; RECOMBINANT PROTEINS; RISK ASSESSMENT; RISK FACTORS; TISSUE SCAFFOLDS;

EID: 84952683422     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.3277     Document Type: Article

References (159)

1. Akiyoshi T, Ito M, Murase S, Miyazaki M, Guengerich FP, Nakamura K, Yamamoto K, Ohtani H. 2013. Mechanism-based inhibition profiles of erythromycin and clarithromycin with cytochrome P450 3A4 genetic variants. Drug Metab. Pharmacokinet. 28(5): 411-415.
2. Amacher DE. 2012. The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury. Expert Opin. Drug Metab. Toxicol. 8(3): 335-347.
3. Aninat C, Piton A, Glaise D, Le Charpentier T, Langouet S, Morel F, Guguen-Guillouzo C, Guillouzo A. 2006. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab. Dispos. 34: 75-83.
4. Ansede JH, Smith WR, Perry CH, St Claire RL, 3rd, Brouwer KR. 2010. An in vitro assay to assess transporter-based cholestatic hepatotoxicity using sandwich-cultured rat hepatocytes. Drug Metab. Dispos. 38(2): 276-280.
5. Antherieu S, Bachour-El Azzi P, Dumont J, Abdel-Razzak Z, Guguen-Guillouzo C, Fromenty B, Robin MA, Guillouzo A. 2013. Oxidative stress plays a major role in chlorpromazine-induced cholestasis in human HepaRG cells. Hepatology 57(4): 1518-1529.
6. Argoti D, Liang L, Conteh A, Chen L, Bershas D, Yu CP, Vouros P, Yang E. 2005. Cyanide trapping of iminium ion reactive intermediates followed by detection and structure identification using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Chem. Res. Toxicol. 18(10): 1537-1544.
7. Ariyoshi N, Iga Y, Hirata K, Sato Y, Miura G, Ishii I, Nagamori S, Kitada M. 2010. Enhanced susceptibility of HLA-mediated ticlopidine-induced idiosyncratic hepatotoxicity by CYP2B6 polymorphism in Japanese. Drug Metab. Pharmacokinet. 25(3): 298-306.
8. Attia SM. 2010. Deleterious effects of reactive metabolites. Oxid. Med. Cell. Longev. 3(4): 238-253.
9. Bai J, Cederbaum AI. 2004. Adenovirus mediated overexpression of CYP2E1 increases sensitivity of HepG2 cells to acetaminophen induced cytotoxicity. Mol. Cell. Biochem. 262(1-2): 165-176.
10. Bauman JN, Kelly JM, Tripathy S, Zhao SX, Lam WW, Kalgutkar AS, Obach RS. 2009. Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction. Chem. Res. Toxicol. 22(2): 332-340.
11. Baxter MA, Rowe C, Alder J, Harrison S, Hanley KP, Park BK, Kitteringham NR, Goldring CE, Hanley NA. 2010. Generating hepatic cell lineages from pluripotent stem cells for drug toxicity screening. Stem Cell Res. 5: 4-22.
12. Beger RD, Sun J, Schnackenberg LK. 2010. Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicol. Appl. Pharmacol. 243(2): 154-166.
13. Bhatia SN, Ingber DE. 2014. Microfluidic organs-on-chips. Nat. Biotechnol. 32(8): 760-772.
14. Biour M, Poupon R, Grange JD, Chazouilleres O. 2000. [Drug-induced hepatotoxicity. The 13th updated edition of the bibliographic database of drug-related liver injuries and responsible drugs]. Gastroenterol. Clin. Biol. 24(11): 1052-1091.
15. Bjornsson ES. 2015. Drug-induced liver injury: an overview over the most critical compounds. Arch. Toxicol. 89(3): 327-334.
16. Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. 2013. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 144(7): 1419-1425, 1425 e1411-1413; quiz e1419-1420.
17. Boelsterli UA, Lim PL. 2007. Mitochondrial abnormalities - a link to idiosyncratic drug hepatotoxicity? Toxicol. Appl. Pharmacol. 220: 92-107.
18. Brandon EF, Raap CD, Meijerman I, Beijnen JH, Schellens JH. 2003. An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol. Appl. Pharmacol. 189(3): 233-246.
19. Burkard A, Dahn C, Heinz S, Zutavern A, Sonntag-Buck V, Maltman D, Przyborski S, Hewitt NJ, Braspenning J. 2012. Generation of proliferating human hepatocytes using Upcyte(R) technology: characterisation and applications in induction and cytotoxicity assays. Xenobiotica 42(10): 939-956.
20. Caplin JD, Granados NG, James MR, Montazami R, Hashemi N. 2015. Microfluidic organ-on-a-chip technology for advancement of drug development and toxicology. Adv. Healthc. Mater. 4(10): 1426-1450.
21. Castell JV, Hernandez D, Gomez-Foix AM, Guillen I, Donato T, Gómez-Lechón MJ. 1997. Adenovirus-mediated gene transfer into human hepatocytes: analysis of the biochemical functionality of transduced cells. Gene Ther. 4(5): 455-464.
22. Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ. 2014. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am. J. Gastroenterol. 109(7): 950-966; quiz 967.
23. Chen M, Bisgin H, Tong L, Hong H, Fang H, Borlak J, Tong W. 2014. Towards predictive models for drug-induced liver injury in humans: are we there yet? Biomark. Med. 8(2): 201-213.
24. Choi JM, Oh SJ, Lee JY, Jeon JS, Ryu CS, Kim YM, Lee K, Kim SK. 2015. Prediction of drug-induced liver injury in HepG2 cells cultured with human liver microsomes. Chem. Res. Toxicol. 28(5): 872-885.
25. Coulet M, Dacasto M, Eeckhoutte C, Larrieu G, Sutra JF, Alvinerie M, Mace K, Pfeifer AM, Galtier P. 1998. Identification of human and rabbit cytochromes P450 1A2 as major isoforms involved in thiabendazole 5-hydroxylation. Fundam. Clin. Pharmacol. 12(2): 225-235.
26. Dalvie D, Kalgutkar AS, Chen W. 2015. Practical approaches to resolving reactive metabolite liabilities in early discovery. Drug Metab. Rev. 47: 56-70.
27. Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP. 2007. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 132: 272-281.
28. Dambach DM, Andrews BA, Moulin F. 2005. New technologies and screening strategies for hepatotoxicity: use of in vitro models. Toxicol. Pathol. 33: 17-26.
29. Davidson MD, Ware BR, Khetani SR. 2015. Stem cell-derived liver cells for drug testing and disease modeling. Discov. Med. 19(106): 349-358.
30. De Bruyn T, Chatterjee S, Fattah S, Keemink J, Nicolai J, Augustijns P, Annaert P. 2013. Sandwich-cultured hepatocytes: utility for in vitro exploration of hepatobiliary drug disposition and drug-induced hepatotoxicity. Expert Opin. Drug Metab. Toxicol. 9(5): 589-616.
31. Donato MT, Lahoz A, Castell JV, Gómez-Lechón MJ. 2008. Cell lines: a tool for in vitro drug metabolism studies. Curr. Drug Metab. 9: 1-11.
32. Donato MT, Hallifax D, Picazo L, Castell JV, Houston JB, Gómez-Lechón MJ, Lahoz A. 2010. Metabolite formation kinetics and intrinsic clearance of phenacetin, tolbutamide, alprazolam, and midazolam in adenoviral cytochrome P450-transfected HepG2 cells and comparison with hepatocytes and in vivo. Drug Metab. Dispos. 38(9): 1449-1455.
33. Donato MT, Jover R, Gómez-Lechón MJ. 2013. Hepatic cell lines for drug hepatotoxicity testing: limitations and strategies to upgrade their metabolic competence by gene engineering. Curr. Drug Metab. 14(9): 946-968.
34. Doss GA, Baillie TA. 2006. Addressing metabolic activation as an integral component of drug design. Drug Metab. Rev. 38(4): 641-649.
35. Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA. 2004. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 17: 3-16.
36. Filppula AM, Neuvonen PJ, Backman JT. 2014. In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab. Dispos. 42(7): 1202-1209.
37. Fontana RJ. 2014. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology 146(4): 914-928.
38. Forestiero FJ, Cecon L, Hirata MH, de Melo FF, Cardoso RF, Cerda A, Hirata RD. 2013. Relationship of NAT2, CYP2E1 and GSTM1/GSTT1 polymorphisms with mild elevation of liver enzymes in Brazilian individuals under anti-tuberculosis drug therapy. Clin. Chim. Acta 415: 215-219.
39. Gan J, Harper TW, Hsueh MM, Qu Q, Humphreys WG. 2005. Dansyl glutathione as a trapping agent for the quantitative estimation and identification of reactive metabolites. Chem. Res. Toxicol. 18(5): 896-903.
40. Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, Bode JG, Bolleyn J, Borner C, Bottger J, Braeuning A, Budinsky RA, Burkhardt B, Cameron NR, Camussi G, Cho CS, Choi YJ, Craig Rowlands J, Dahmen U, Damm G, Dirsch O, Donato MT, Dong J, Dooley S, Drasdo D, Eakins R, Ferreira KS, Fonsato V, Fraczek J, Gebhardt R, Gibson A, Glanemann M, Goldring CE, Gómez-Lechón MJ, Groothuis GM, Gustavsson L, Guyot C, Hallifax D, Hammad S, Hayward A, Haussinger D, Hellerbrand C, Hewitt P, Hoehme S, Holzhutter HG, Houston JB, Hrach J, Ito K, Jaeschke H, Keitel V, Kelm JM, Kevin Park B, Kordes C, Kullak-Ublick GA, LeCluyse EL, Lu P, Luebke-Wheeler J, Lutz A, Maltman DJ, Matz-Soja M, McMullen P, Merfort I, Messner S, Meyer C, Mwinyi J, Naisbitt DJ, Nussler AK, Olinga P, Pampaloni F, Pi J, Pluta L, Przyborski SA, Ramachandran A, Rogiers V, Rowe C, Schelcher C, Schmich K, Schwarz M, Singh B, Stelzer EH, Stieger B, Stober R, Sugiyama Y, Tetta C, Thasler WE, Vanhaecke T, Vinken M, Weiss TS, Widera A, Woods CG, Xu JJ, Yarborough KM, Hengstler JG. 2013. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch. Toxicol. 87(8): 1315-1530.
41. Gómez-Lechón MJ, Donato MT, Castell JV, Jover R. 2003. Human hepatocytes as a tool for studying toxicity and drug metabolism. Curr. Drug Metab. 4(4): 292-312.
42. Gómez-Lechón MJ, Donato MT, Castell JV, Jover R. 2004. Human hepatocytes in primary culture: the choice to investigate drug metabolism in man. Curr. Drug Metab. 5(5): 443-462.
43. Gómez-Lechón MJ, Lahoz A, Gombau L, Castell JV, Donato MT. 2010. In vitro evaluation of potential hepatotoxicity induced by drugs. Curr. Pharm. Des. 16(17): 1963-1977.
44. Gómez-Lechón MJ, Tolosa L, Conde I, Donato MT. 2014. Competency of different cell models to predict human hepatotoxic drugs. Expert Opin. Drug Metab. Toxicol. 10(11): 1553-1568.
45. Graaf IA, Groothuis GM, Olinga P. 2007. Precision-cut tissue slices as a tool to predict metabolism of novel drugs. Expert Opin. Drug Metab. Toxicol. 3(6): 879-898.
46. Greer ML, Barber J, Eakins J, Kenna JG. 2010. Cell based approaches for evaluation of drug-induced liver injury. Toxicology 268(3): 125-131.
47. Guengerich FP. 2011. Mechanisms of drug toxicity and relevance to pharmaceutical development. Drug Metab. Pharmacokinet. 26: 3-14.
48. Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F, Guguen-Guillouzo C. 2007. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem. Biol. Interact. 168: 66-73.
49. Gunness P, Mueller D, Shevchenko V, Heinzle E, Ingelman-Sundberg M, Noor F. 2013. 3D organotypic cultures of human HepaRG cells: a tool for in vitro toxicity studies. Toxicol. Sci. 133: 67-78.
50. Gustafsson F, Foster AJ, Sarda S, Bridgland-Taylor MH, Kenna JG. 2014. A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. Toxicol. Sci. 137: 189-211.
51. Hadem J, Tacke F, Bruns T, Langgartner J, Strnad P, Denk GU, Fikatas P, Manns MP, Hofmann WP, Gerken G, Grunhage F, Umgelter A, Trautwein C, Canbay A. 2012. Etiologies and outcomes of acute liver failure in Germany. Clin. Gastroenterol. Hepatol. 10(6): 664-669, e662.
52. Hadi M, Chen Y, Starokozhko V, Merema MT, Groothuis GM. 2012. Mouse precision-cut liver slices as an ex vivo model to study idiosyncratic drug-induced liver injury. Chem. Res. Toxicol. 25(9): 1938-1947.
53. Hadi M, Westra IM, Starokozhko V, Dragovic S, Merema MT, Groothuis GM. 2013. Human precision-cut liver slices as an ex vivo model to study idiosyncratic drug-induced liver injury. Chem. Res. Toxicol. 26(5): 710-720.
54. Han D, Dara L, Win S, Than TA, Yuan L, Abbasi SQ, Liu ZX, Kaplowitz N. 2013. Regulation of drug-induced liver injury by signal transduction pathways: critical role of mitochondria. Trends Pharmacol. Sci. 34(4): 243-253.
55. Hardy KD, Wahlin MD, Papageorgiou I, Unadkat JD, Rettie AE, Nelson SD. 2014. Studies on the role of metabolic activation in tyrosine kinase inhibitor-dependent hepatotoxicity: induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cells. Drug Metab. Dispos. 42: 162-171.
56. Hewitt M, Enoch SJ, Madden JC, Przybylak KR, Cronin MT. 2013. Hepatotoxicity: a scheme for generating chemical categories for read-across, structural alerts and insights into mechanism(s) of action. Crit. Rev. Toxicol. 43(7): 537-558.
57. Hoos JS, Damsten MC, de Vlieger JS, Commandeur JN, Vermeulen NP, Niessen WM, Lingeman H, Irth H. 2007. Automated detection of covalent adducts to human serum albumin by immunoaffinity chromatography, on-line solution phase digestion and liquid chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 859(2): 147-156.
58. Hosomi H, Akai S, Minami K, Yoshikawa Y, Fukami T, Nakajima M, Yokoi T. 2010. An in vitro drug-induced hepatotoxicity screening system using CYP3A4-expressing and gamma-glutamylcysteine synthetase knockdown cells. Toxicol. In Vitro 24(3): 1032-1038.
59. Hosomi H, Fukami T, Iwamura A, Nakajima M, Yokoi T. 2011. Development of a highly sensitive cytotoxicity assay system for CYP3A4-mediated metabolic activation. Drug Metab. Dispos. 39(8): 1388-1395.
60. Huang K, Huang L, van Breemen RB. 2015. Detection of reactive metabolites using isotope-labeled glutathione trapping and simultaneous neutral loss and precursor ion scanning with ultra-high-pressure liquid chromatography triple quadruple mass spectrometry. Anal. Chem. 87(7): 3646-3654.
61. Ioannides C, Lewis DF. 2004. Cytochromes P450 in the bioactivation of chemicals. Curr. Top. Med. Chem. 4(16): 1767-1788.
62. Jetten MJ, Claessen SM, Dejong CH, Lahoz A, Castell JV, van Delft JH, Kleinjans JC. 2014. Interindividual variation in response to xenobiotic exposure established in precision-cut human liver slices. Toxicology 323: 61-69.
63. Jiang J, Wolters JE, van Breda SG, Kleinjans JC, de Kok TM. 2015. Development of novel tools for the in vitro investigation of drug-induced liver injury. Expert Opin. Drug Metab. Toxicol. 11(10): 1523-1537.
64. Kalgutkar AS. 2015. Should the incorporation of structural alerts be restricted in drug design? An analysis of structure-toxicity trends with aniline-based drugs. Curr. Med. Chem. 22(4): 438-464.
65. Kalgutkar AS, Didiuk MT. 2009. Structural alerts, reactive metabolites, and protein covalent binding: how reliable are these attributes as predictors of drug toxicity? Chem. Biodivers. 6(11): 2115-2137.
66. Kalgutkar AS, Soglia JR. 2005. Minimising the potential for metabolic activation in drug discovery. Expert Opin. Drug Metab. Toxicol. 1: 91-142.
67. Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, Callegari E, Henne KR, Mutlib AE, Dalvie DK, Lee JS, Nakai Y, O'Donnell JP, Boer J, Harriman SP. 2005. A comprehensive listing of bioactivation pathways of organic functional groups. Curr. Drug Metab. 6(3): 161-225.
68. Kanebratt KP, Andersson TB. 2008. Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab. Dispos. 36(7): 1444-1452.
69. Kenaan C, Zhang H, Hollenberg PF. 2013. High-throughput fluorescence assay for cytochrome P450 mechanism-based inactivators. Methods Mol. Biol. 987: 61-69.
70. Kenny JR, Mukadam S, Zhang C, Tay S, Collins C, Galetin A, Khojasteh SC. 2012. Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction. Pharm. Res. 29(7): 1960-1976.
71. Kent UM, Juschyshyn MI, Hollenberg PF. 2001. Mechanism-based inactivators as probes of cytochrome P450 structure and function. Curr. Drug Metab. 2(3): 215-243.
72. Kia R, Sison RL, Heslop J, Kitteringham NR, Hanley N, Mills JS, Park BK, Goldring CE. 2013. Stem cell-derived hepatocytes as a predictive model for drug-induced liver injury: are we there yet? Br. J. Clin. Pharmacol. 75(4): 885-896.
73. Kondo Y, Iwao T, Nakamura K, Sasaki T, Takahashi S, Kamada N, Matsubara T, Gonzalez FJ, Akutsu H, Miyagawa Y, Okita H, Kiyokawa N, Toyoda M, Umezawa A, Nagata K, Matsunaga T, Ohmori S. 2014. An efficient method for differentiation of human induced pluripotent stem cells into hepatocyte-like cells retaining drug metabolizing activity. Drug Metab. Pharmacokinet. 29(3): 237-243.
74. Kostadinova R, Boess F, Applegate D, Suter L, Weiser T, Singer T, Naughton B, Roth A. 2013. A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity. Toxicol. Appl. Pharmacol. 268: 1-16.
75. Kwon SJ, Lee DW, Shah DA, Ku B, Jeon SY, Solanki K, Ryan JD, Clark DS, Dordick JS, Lee MY. 2014. High-throughput and combinatorial gene expression on a chip for metabolism-induced toxicology screening. Nat. Commun. 5: 3739.
76. Labbe G, Pessayre D, Fromenty B. 2008. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam. Clin. Pharmacol. 22(4): 335-353.
77. Lammert C, Bjornsson E, Niklasson A, Chalasani N. 2010. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 51(2): 615-620.
78. Laurent V, Fraix A, Montier T, Cammas-Marion S, Ribault C, Benvegnu T, Jaffres PA, Loyer P. 2010. Highly efficient gene transfer into hepatocyte-like HepaRG cells: new means for drug metabolism and toxicity studies. Biotechnol. J. 5(3): 314-320.
79. Leblanc A, Shiao TC, Roy R, Sleno L. 2010. Improved detection of reactive metabolites with a bromine-containing glutathione analog using mass defect and isotope pattern matching. Rapid Commun. Mass Spectrom. 24(9): 1241-1250.
80. Leite SB, Wilk-Zasadna I, Zaldivar JM, Airola E, Reis-Fernandes MA, Mennecozzi M, Guguen-Guillouzo C, Chesne C, Guillou C, Alves PM, Coecke S. 2012. Three-dimensional HepaRG model as an attractive tool for toxicity testing. Toxicol. Sci. 130: 106-116.
81. Leung L, Kalgutkar AS, Obach RS. 2012. Metabolic activation in drug-induced liver injury. Drug Metab. Rev. 44: 18-33.
82. Lewis DF, Ioannides C, Parke DV. 1998. Cytochromes P450 and species differences in xenobiotic metabolism and activation of carcinogen. Environ. Health Perspect. 106(10): 633-641.
83. Lim HK, Duczak N, Jr, Brougham L, Elliot M, Patel K, Chan K. 2005. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes. Drug Metab. Dispos. 33(8): 1211-1219.
84. Liu R, Yu X, Wallqvist A. 2015. Data-driven identification of structural alerts for mitigating the risk of drug-induced human liver injuries. J. Cheminform. 7: 4.
85. Long A. 2013. Drug metabolism in silico - the knowledge-based expert system approach. Historical perspectives and current strategies. Drug Discov. Today Technol. 10: e147-e153.
86. Lopachin RM, Gavin T, Decaprio A, Barber DS. 2012. Application of the hard and soft, acids and bases (HSAB) theory to toxicant-target interactions. Chem. Res. Toxicol. 25(2): 239-251.
87. Ly VT, Brock B. 2011. Effects of CYP inhibitors on precocene I metabolism and toxicity in rat liver slices. Chem. Biol. Interact. 193(2): 109-118.
88. MacDonald C, Smith C, Michopoulos F, Weaver R, Wilson ID. 2011. Identification and quantification of glutathione adducts of clozapine using ultra-high-performance liquid chromatography with orthogonal acceleration time-of-flight mass spectrometry and inductively coupled plasma mass spectrometry. Rapid Commun. Mass Spectrom. 25(13): 1787-1793.
89. Mace K, Aguilar F, Wang JS, Vautravers P, Gómez-Lechón M, Gonzalez FJ, Groopman J, Harris CC, Pfeifer AM. 1997. Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. Carcinogenesis 18(7): 1291-1297.
90. Mann DA. 2015. Human induced pluripotent stem cell-derived hepatocytes for toxicology testing. Expert Opin. Drug Metab. Toxicol. 11: 1-5.
91. Maschmeyer I, Lorenz AK, Schimek K, Hasenberg T, Ramme AP, Hubner J, Lindner M, Drewell C, Bauer S, Thomas A, Sambo NS, Sonntag F, Lauster R, Marx U. 2015. A four-organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents. Lab Chip 15(12): 2688-2699.
92. McGill MR, Yan HM, Ramachandran A, Murray GJ, Rollins DE, Jaeschke H. 2011. HepaRG cells: a human model to study mechanisms of acetaminophen hepatotoxicity. Hepatology 53(3): 974-982.
93. Medine CN, Lucendo-Villarin B, Storck C, Wang F, Szkolnicka D, Khan F, Pernagallo S, Black JR, Marriage HM, Ross JA, Bradley M, Iredale JP, Flint O, Hay DC. 2013. Developing high-fidelity hepatotoxicity models from pluripotent stem cells. Stem Cells Transl. Med. 2(7): 505-509.
94. Meneses-Lorente G, Sakatis MZ, Schulz-Utermoehl T, De Nardi C, Watt AP. 2006. A quantitative high-throughput trapping assay as a measurement of potential for bioactivation. Anal. Biochem. 351(2): 266-272.
95. Mikami A, Ohtani H, Hori S, Sawada Y. 2013. Pharmacokinetic model incorporating mechanism-based inactivation of CYP2D6 can explain both non-linear kinetics and drug interactions of paroxetine. Int. J. Clin. Pharmacol. Ther. 51(5): 374-382.
96. Mitchell MD, Elrick MM, Walgren JL, Mueller RA, Morris DL, Thompson DC. 2008. Peptide-based in vitro assay for the detection of reactive metabolites. Chem. Res. Toxicol. 21(4): 859-868.
97. Molden E, Asberg A, Christensen H. 2000. CYP2D6 is involved in O-demethylation of diltiazem. An in vitro study with transfected human liver cells. Eur. J. Clin. Pharmacol. 56(8): 575-579.
98. Norris W, Paredes AH, Lewis JH. 2008. Drug-induced liver injury in 2007. Curr. Opin. Gastroenterol. 24(3): 287-297.
99. O'Brien PJ, Chan K, Silber PM. 2004. Human and animal hepatocytes in vitro with extrapolation in vivo. Chem. Biol. Interact. 150: 97-114.
100. Obach RS, Walsky RL, Venkatakrishnan K. 2007. Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab. Dispos. 35(2): 246-255.
101. Obach RS, Kalgutkar AS, Soglia JR, Zhao SX. 2008. Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem. Res. Toxicol. 21(9): 1814-1822.
102. Ohkura T, Ohta K, Nagao T, Kusumoto K, Koeda A, Ueda T, Jomura T, Ikeya T, Ozeki E, Wada K, Naitoh K, Inoue Y, Takahashi N, Iwai H, Arakawa H, Ogihara T. 2014. Evaluation of human hepatocytes cultured by three-dimensional spheroid systems for drug metabolism. Drug Metab. Pharmacokinet. 29(5): 373-378.
103. Olinga P, Groen K, Hof IH, De Kanter R, Koster HJ, Leeman WR, Rutten AA, Van Twillert K, Groothuis GM. 1997. Comparison of five incubation systems for rat liver slices using functional and viability parameters. J. Pharmacol. Toxicol. Methods 38(2): 59-69.
104. Orhan H, Vermeulen NP. 2011. Conventional and novel approaches in generating and characterization of reactive intermediates from drugs/drug candidates. Curr. Drug Metab. 12(4): 383-394.
105. Orr ST, Ripp SL, Ballard TE, Henderson JL, Scott DO, Obach RS, Sun H, Kalgutkar AS. 2012. Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks. J. Med. Chem. 55(11): 4896-4933.
106. Otto M, Hansen SH, Dalgaard L, Dubois J, Badolo L. 2008. Development of an in vitro assay for the investigation of metabolism-induced drug hepatotoxicity. Cell Biol. Toxicol. 24: 87-99.
107. Pahler A, Brink A. 2013. Software aided approaches to structure-based metabolite identification in drug discovery and development. Drug Discov. Today Technol. 10: e207-e217.
108. Park BK, Laverty H, Srivastava A, Antoine DJ, Naisbitt D, Williams DP. 2011. Drug bioactivation and protein adduct formation in the pathogenesis of drug-induced toxicity. Chem. Biol. Interact. 192(1-2): 30-36.
109. Pelkonen O, Pasanen M, Tolonen A, Koskinen M, Hakkola J, Abass K, Laine J, Hakkinen M, Juvonen R, Auriola S, Storvik M, Huuskonen P, Rousu T, Rahikkala M. 2015. Reactive metabolites in early drug development: predictive in vitro tools. Curr. Med. Chem. 22(4): 538-550.
110. Pessayre D, Fromenty B, Berson A, Robin MA, Letteron P, Moreau R, Mansouri A. 2012. Central role of mitochondria in drug-induced liver injury. Drug Metab. Rev. 44: 34-87.
111. Pfeifer AM, Cole KE, Smoot DT, Weston A, Groopman JD, Shields PG, Vignaud JM, Juillerat M, Lipsky MM, Trump BF et al. 1993. Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens. Proc. Natl. Acad. Sci. U. S. A. 90(11): 5123-5127.
112. Polasek TM, Miners JO. 2007. In vitro approaches to investigate mechanism-based inactivation of CYP enzymes. Expert Opin. Drug Metab. Toxicol. 3(3): 321-329.
113. Prakash C, Sharma R, Gleave M, Nedderman A. 2008. In vitro screening techniques for reactive metabolites for minimizing bioactivation potential in drug discovery. Curr. Drug Metab. 9(9): 952-964.
114. Reuben A, Koch DG, Lee WM. 2010. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 52(6): 2065-2076.
115. Ringel M, von Mach MA, Santos R, Feilen PJ, Brulport M, Hermes M, Bauer AW, Schormann W, Tanner B, Schon MR, Oesch F, Hengstler JG. 2005. Hepatocytes cultured in alginate microspheres: an optimized technique to study enzyme induction. Toxicology 206: 153-167.
116. Roth RA, Ganey PE. 2010. Intrinsic versus idiosyncratic drug-induced hepatotoxicity - two villains or one? J. Pharmacol. Exp. Ther. 332(3): 692-697.
117. Roth RA, Ganey PE. 2011. Animal models of idiosyncratic drug-induced liver injury - current status. Crit. Rev. Toxicol. 41(9): 723-739.
118. Rousu T, Pelkonen O, Tolonen A. 2009. Rapid detection and characterization of reactive drug metabolites in vitro using several isotope-labeled trapping agents and ultra-performance liquid chromatography/time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 23(6): 843-855.
119. Rybacka A, Ruden C, Andersson PL. 2014. On the use of in silico tools for prioritising toxicity testing of the low-volume industrial chemicals in REACH. Basic Clin. Pharmacol. Toxicol. 115: 77-87.
120. Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE. 2012. Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chem. Res. Toxicol. 25(10): 2067-2082.
121. Sanderson JP, Naisbitt DJ, Park BK. 2006. Role of bioactivation in drug-induced hypersensitivity reactions. AAPS J. 8: E55-E64.
122. Sarkar U, Rivera-Burgos D, Large EM, Hughes DJ, Ravindra KC, Dyer RL, Ebrahimkhani MR, Wishnok JS, Griffith LG, Tannenbaum SR. 2015. Metabolite profiling and pharmacokinetic evaluation of hydrocortisone in a perfused three-dimensional human liver bioreactor. Drug Metab. Dispos. 43(7): 1091-1099.
123. Schyschka L, Sanchez JJ, Wang Z, Burkhardt B, Muller-Vieira U, Zeilinger K, Bachmann A, Nadalin S, Damm G, Nussler AK. 2013. Hepatic 3D cultures but not 2D cultures preserve specific transporter activity for acetaminophen-induced hepatotoxicity. Arch. Toxicol. 87(8): 1581-1593.
124. Shaw PJ, Ganey PE, Roth RA. 2010. Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. Toxicol. Sci. 118: 7-18.
125. Si-Tayeb K, Noto FK, Nagaoka M, Li J, Battle MA, Duris C, North PE, Dalton S, Duncan SA. 2010. Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology 51: 297-305.
126. Soglia JR, Harriman SP, Zhao S, Barberia J, Cole MJ, Boyd JG, Contillo LG. 2004. The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro-electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent. J. Pharm. Biomed. Anal. 36: 105-116.
127. Soldatow VY, Lecluyse EL, Griffith LG, Rusyn I. 2013. models for liver toxicity testing. Toxicol. Res. (Camb.) 2: 23-39.
128. Srivastava A, Maggs JL, Antoine DJ, Williams DP, Smith DA, Park BK. 2010. Role of reactive metabolites in drug-induced hepatotoxicity. Handb. Exp. Pharmacol. 196: 165-194.
129. Stepan AF, Walker DP, Bauman J, Price DA, Baillie TA, Kalgutkar AS, Aleo MD. 2011. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem. Res. Toxicol. 24(9): 1345-1410.
130. Takahashi Y, Hori Y, Yamamoto T, Urashima T, Ohara Y, Tanaka H. 2015. Three-dimensional (3D) spheroid cultures improve the metabolic gene expression profiles of HepaRG cells. Biosci. Rep. 35(3): e00208.
131. Takakusa H, Masumoto H, Makino C, Okazaki O, Sudo K. 2009. Quantitative assessment of reactive metabolite formation using 35S-labeled glutathione. Drug Metab. Pharmacokinet. 24: 100-107.
132. Takayama K, Morisaki Y, Kuno S, Nagamoto Y, Harada K, Furukawa N, Ohtaka M, Nishimura K, Imagawa K, Sakurai F, Tachibana M, Sumazaki R, Noguchi E, Nakanishi M, Hirata K, Kawabata K, Mizuguchi H. 2014. Prediction of interindividual differences in hepatic functions and drug sensitivity by using human iPS-derived hepatocytes. Proc. Natl. Acad. Sci. U. S. A. 111(47): 16772-16777.
133. Tania M, Hsu MN, Png SN, Leo HL, Toh GW, Birgersson E. 2014. Perfusion enhanced polydimethylsiloxane based scaffold cell culturing system for multi-well drug screening platform. Biotechnol. Prog. 30(2): 418-428.
134. Taxak N, Bharatam PV. 2010. An insight into the concept and details of mechanism-based inhibition of CYP450. Curr. Res. Info. Pharmaceut. Sci. 11: 62-67.
135. Testa B, Balmat AL, Long A, Judson P. 2005. Predicting drug metabolism - an evaluation of the expert system METEOR. Chem. Biodivers. 2(7): 872-885.
136. Thompson RA, Isin EM, Li Y, Weaver R, Weidolf L, Wilson I, Claesson A, Page K, Dolgos H, Kenna JG. 2011. Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. Chem. Biol. Interact. 192(1-2): 65-71.
137. Thompson RA, Isin EM, Li Y, Weidolf L, Page K, Wilson I, Swallow S, Middleton B, Stahl S, Foster AJ, Dolgos H, Weaver R, Kenna JG. 2012. In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. Chem. Res. Toxicol. 25(8): 1616-1632.
138. Thorsell A, Isin EM, Jurva U. 2014. Use of electrochemical oxidation and model peptides to study nucleophilic biological targets of reactive metabolites: the case of rimonabant. Chem. Res. Toxicol. 27(10): 1808-1820.
139. Tolosa L, Donato MT, Perez-Cataldo G, Castell JV, Gómez-Lechón MJ. 2012. Upgrading cytochrome P450 activity in HepG2 cells co-transfected with adenoviral vectors for drug hepatotoxicity assessment. Toxicol. In Vitro 26(8): 1272-1277.
140. Tolosa L, Gómez-Lechón MJ, Perez-Cataldo G, Castell JV, Donato MT. 2013. HepG2 cells simultaneously expressing five P450 enzymes for the screening of hepatotoxicity: identification of bioactivable drugs and the potential mechanism of toxicity involved. Arch. Toxicol. 87(6): 1115-1127.
141. Tornio A, Filppula AM, Kailari O, Neuvonen M, Nyronen TH, Tapaninen T, Neuvonen PJ, Niemi M, Backman JT. 2014. Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions. Clin. Pharmacol. Ther. 96(4): 498-507.
142. Tostoes RM, Leite SB, Serra M, Jensen J, Bjorquist P, Carrondo MJ, Brito C, Alves PM. 2012. Human liver cell spheroids in extended perfusion bioreactor culture for repeated-dose drug testing. Hepatology 55(4): 1227-1236.
143. Uetrecht J. 2007. Idiosyncratic drug reactions: current understanding. Annu. Rev. Pharmacol. Toxicol. 47: 513-539.
144. Ulrich RG. 2007. Idiosyncratic toxicity: a convergence of risk factors. Annu. Rev. Med. 58: 17-34.
145. Valerio LG, Jr, Long A. 2010. The in silico prediction of human-specific metabolites from hepatotoxic drugs. Curr. Drug Discov. Technol. 7(3): 170-187.
146. van den Brink FT, Buter L, Odijk M, Olthuis W, Karst U, van den Berg A. 2015. Mass spectrometric detection of short-lived drug metabolites generated in an electrochemical microfluidic chip. Anal. Chem. 87(3): 1527-1535.
147. Van den Hof WF, Van Summeren A, Lommen A, Coonen ML, Brauers K, van Herwijnen M, Wodzig WK, Kleinjans JC. 2014. Integrative cross-omics analysis in primary mouse hepatocytes unravels mechanisms of cyclosporin A-induced hepatotoxicity. Toxicology 324: 18-26.
148. Vickers AE. 2009. Tissue slices for the evaluation of metabolism-based toxicity with the example of diclofenac. Chem. Biol. Interact. 179: 9-16.
149. Vignati L, Turlizzi E, Monaci S, Grossi P, Kanter R, Monshouwer M. 2005. An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics. Toxicology 216(2-3): 154-167.
150. Walgren JL, Mitchell MD, Thompson DC. 2005. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol. 35(4): 325-361.
151. Worboys PD, Bradbury A, Houston JB. 1997. Kinetics of drug metabolism in rat liver slices. III. Relationship between metabolic clearance and slice uptake rate. Drug Metab. Dispos. 25(4): 460-467.
152. Xu JJ, Henstock PV, Dunn MC, Smith AR, Chabot JR, de Graaf D. 2008. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci. 105: 97-105.
153. Xu S, Zhu B, Teffera Y, Pan DE, Caldwell CG, Doss G, Stearns RA, Evans DC, Beconi MG. 2005. Metabolic activation of fluoropyrrolidine dipeptidyl peptidase-IV inhibitors by rat liver microsomes. Drug Metab. Dispos. 33: 121-130.
154. Yan Z, Maher N, Torres R, Huebert N. 2007. Use of a trapping agent for simultaneous capturing and high-throughput screening of both "soft" and "hard" reactive metabolites. Anal. Chem. 79(11): 4206-4214.
155. Yang Y, Xiao Q, Humphreys WG, Dongre A, Shu YZ. 2014. Identification of human liver microsomal proteins adducted by a reactive metabolite using shotgun proteomics. Chem. Res. Toxicol. 27(9): 1537-1546.
156. Yano A, Oda S, Fukami T, Nakajima M, Yokoi T. 2014. Development of a cell-based assay system considering drug metabolism and immune- and inflammatory-related factors for the risk assessment of drug-induced liver injury. Toxicol. Lett. 228: 13-24.
157. Yi F, Liu GH, Izpisua Belmonte JC. 2012. Human induced pluripotent stem cells derived hepatocytes: rising promise for disease modeling, drug development and cell therapy. Protein Cell 3(4): 246-250.
158. Zhang X, Liu F, Chen X, Zhu X, Uetrecht J. 2011. Involvement of the immune system in idiosyncratic drug reactions. Drug Metab. Pharmacokinet. 26: 47-59.
159. Zhou S, Chan E, Duan W, Huang M, Chen YZ. 2005. Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab. Rev. 37: 41-213.